AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04891224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pathway Platform mobile app
Description: The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
Study NCT05291390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyronaridine Tetraphosphate
Description: Via oral capsules.
Study NCT05291390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine Tetraphosphate
Description: Via oral capsules.
Study NCT05928442 — intervention group
Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 2 saliva samples at inclusion.
Study NCT05928442 — intervention group
Intervention type: BEHAVIORAL
Intervention: Completion of a self-questionnaire
Description: Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
Study NCT05928442 — intervention group
Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 1 saliva sample at the follow-up visit.
Study NCT05219136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Fasting Group
Description: a new fasting protocol is applied to subjects.
Study NCT05219136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fasting Group
Description: a conventional fasting protocol is applied to subjects.
Study NCT05616312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Teach Back
Description: Patients will receive teach-back education while they fill out questionnaires.
Study NCT06585735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme fortified protein supplement
Description: Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
Study NCT06585735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proteolytic enzyme fortified protein supplement
Description: Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
Study NCT05699668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: 2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds.
Study NCT05525182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 40 mg
Description: Composition: Elaeocarpus extract 40mg tablet
Study NCT05525182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 80 mg
Description: Elaeocarpus extract 80 mg tablet
Study NCT05525182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 160 mg
Description: Elaeocarpus extract 160 mg tablet
Study NCT05525182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
Study NCT04874506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-02
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Study NCT06539026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid therapy, 300 ml of crystalloid Ringer's solution.
Description: 300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg.
Study NCT05855863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Ketone Ester Tablets
Description: Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Study NCT05855863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Study NCT05498948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic mixture
Description: orally take .
Study NCT05498948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: orally take .
Study NCT06171919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organizational Partnerships
Description: Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
Study NCT06171919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Continuum Care
Description: Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
Study NCT06515639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet therapy for Classic IF diet group
Description: The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
Study NCT06515639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet therapy for low carb-High fat IF diet group
Description: The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
Study NCT06566001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: socket shield technique and allogenic bone graft
Study NCT04749290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Formula
Description: Study infant formula for term infants containing OPO and CPP
Study NCT04749290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula
Description: Study infant formula for term infants containing OPO and CPP
Study NCT05264324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximal Exercise Capacity
Description: Maximal Exercise Capacity in incremental ramp exercise tests.
Study NCT05264324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Exercise Capacity
Description: Maximal Exercise Capacity in incremental ramp exercise tests.
Study NCT06197451 — intervention group
Intervention type: OTHER
Intervention: Turkish Version of M. D. Anderson Dysphagia Inventory
Description: Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
Study NCT06184295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBI - Intervention Group
Description: The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
Study NCT06288347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGON mobile app.
Description: The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
Study NCT06288347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGON mobile app.
Description: The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
Study NCT05936255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give to Others Module
Description: Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
Study NCT06147011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: Slide-based presention plus 3D printed thyroid fine needle aspiration model
Study NCT04719416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Meditation
Description: Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
Study NCT06566222 — intervention group
Intervention type: PROCEDURE
Intervention: chemoradiotherapy after surgery
Description: chemoradiotherapy after surgery vs preoperative chemoradiotherapy
Study NCT06566222 — intervention group
Intervention type: OTHER
Intervention: High-risk Factors
Description: High-risk Factors vs low-risk Factors
Study NCT05927233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
Study NCT04916340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular Strength Training Group
Description: Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM
Study NCT05927233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 30 ml Normal saline
Study NCT04916340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular Fitness Training Group
Description: Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM
Study NCT06059963 — intervention group
Intervention type: DEVICE
Intervention: Signal-C™
Description: Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
Study NCT05681429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib
Description: To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
Study NCT05681429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib
Description: To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
Study NCT06387329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG
Description: No additional information
Study NCT06387329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 MG
Description: No additional information
Study NCT05491603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DBI-001
Description: Topically administered
Study NCT05491603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DBI-002
Description: Topically administered
Study NCT05491603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous Gel
Description: Topically administered
Study NCT06124534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation of the Occipital Nerve Field
Description: BliStim Neurostimulation system
Study NCT06047964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB
Description: Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
Study NCT06047964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: Intracranial PTA balloon catheter
Study NCT05794386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LVA-guided LA substrate modification
Description: The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
Study NCT04587856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bone marrow withdrawal
Description: bone marrow samples evaluation
Study NCT06493110 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric ultrasound
Description: To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
Study NCT04937452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 4Mg/24Hrs Patch
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Study NCT04937452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 6Mg/24Hrs Patch
Description: Rotigotine 6 mg/24Hrs administration for 24 weeks
Study NCT04937452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 24 weeks
Study NCT06341270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
Study NCT06341270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous electrical acupoint stimulation
Description: Patients in the sham group will receive electrode attachment but without stimulation.
Study NCT05847309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed extubation
Description: Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
Study NCT05847309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early extubation
Description: Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
Study NCT05644899 — intervention group
Intervention type: PROCEDURE
Intervention: Interlaminar ultrasound-assisted intrathecal administration of nusinersen
Description: All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
Study NCT05644899 — intervention group
Intervention type: PROCEDURE
Intervention: Landmark-based intrathecal administration of nusinersen
Description: All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
Study NCT06554678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
Description: Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
Study NCT06554678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional oxygen mask
Description: conventional oxygen mask
Study NCT06145399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
Study NCT06145399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging
Description: 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
Study NCT06145399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDHT
Description: 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
Study NCT06566248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3810 tablets+NUC
Description: TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
Study NCT06566248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+NUC
Description: NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication.
Study NCT06644729 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair
Study NCT05972954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: once daily
Study NCT06369077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide/timolol
Description: Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
Study NCT06108297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Elemental lithium as lithium aspartate.